Miller D L, Weinstock M A
Dermatoepidemiology Unit, V.A. Medical Center--111D, Providence, RI 02908.
J Am Acad Dermatol. 1994 May;30(5 Pt 1):774-8. doi: 10.1016/s0190-9622(08)81509-5.
Because death from nonmelanoma skin cancer is uncommon, quantification of its morbidity is particularly important. Although its incidence is increasing rapidly, the most recent nationwide estimates are 16 years old. The purpose of this study was to estimate the 1994 nonmelanoma skin cancer incidence in the United States. We updated the 16-year-old incidence estimates to reflect the growth and changing age distribution of the population and the increases in age-adjusted incidence rates documented in two population-based studies. The projected 1994 incidence of nonmelanoma skin cancer in the United States is 900,000 to 1,200,000 cases, similar in magnitude to the overall incidence of noncutaneous cancers. Nonmelanoma skin cancer imposes an enormous public health burden on the U.S. population. Quantification of its morbidity and its prevention are important priorities.
由于非黑色素瘤皮肤癌导致的死亡并不常见,因此对其发病率进行量化尤为重要。尽管其发病率正在迅速上升,但最新的全国性估计数据已有16年之久。本研究的目的是估算1994年美国非黑色素瘤皮肤癌的发病率。我们更新了已有16年历史的发病率估计数据,以反映人口的增长和年龄分布变化,以及两项基于人群的研究中记录的年龄调整发病率的上升情况。预计1994年美国非黑色素瘤皮肤癌的发病率为90万至120万例,与非皮肤癌的总体发病率规模相当。非黑色素瘤皮肤癌给美国人口带来了巨大的公共卫生负担。对其发病率进行量化及其预防是重要的优先事项。